Did Nulcala get it's first prescription yet?

Discussion in 'GlaxoSmithKline' started by anonymous, Nov 13, 2015 at 10:41 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    another blockbuster?!
     

  2. anonymous

    anonymous Guest

    When is launch date?
     
  3. anonymous

    anonymous Guest

    Well according to one analyst report I saw recently they estimated peak sales of GBP600 million, so just about a blockbuster on the $1 billion criterion.

    Whether it gets there or not we will see but obviously it should bring in some serious money, even $400 million extra is not bad and is yet another product approval. I recall the days in the 2000's where getting one approval was considered great. GSK has had over 8 in the past3-4 years and it is taken for granted.
     
  4. anonymous

    anonymous Guest

    Yes, your comments are spot on. $400 million, $400 million there and voila, you suddenly are talking serious money. I remember some of the idiots in marketing would push back on R&D teams if a drug was not projected to make more than a billion. Many a potential blockbuster were scrapped. You are correct senior management took these number of approvals for granted and some of the best talent that produced these approvals have now left the company due to shortsighted decisions. The expected positive reaction after R&D day fell flat and stock price has declined significantly. Do we still have the talent internally to move these compounds along quickly and flawlessly or will we make mistakes/delays due to not having the best at GSK? If we get them approved can we sell them? GSK has had great sales teams in the past that could sell ice to eskimos, but what about now with 8 calls/day, forced rank ratings, etc?
     
  5. anonymous

    anonymous Guest

    No bonus so who is going to break your neck selling this?
     
  6. anonymous

    anonymous Guest

    Yea a new product Nulcala - just need 100 other new 400 million products to replace the loss of Advair. Still a one note song at GSK.
     
  7. anonymous

    anonymous Guest

    Actually if Nucala was a $400 million product (on the low end of predictions) then we would need around 10 to make up for Advair. We have Breo and Anoro to add to that so already part way there. 100 is just hyperbole.
     
  8. anonymous

    anonymous Guest

    Name a plan that will cover BREO when ADVAIR goes generic... please... name one. GSK couldn't have screwed up the ANORO launch any more than they did if they were actively trying.
     
  9. anonymous

    anonymous Guest

    Stop complaining, do your job, work hard, and smile.......it's as easy as that......if you can't, just quit ! See how easy life can be ?
     
  10. anonymous

    anonymous Guest

    Oh
     
  11. anonymous

    anonymous Guest

    It's great to see you understand.
     
  12. anonymous

    anonymous Guest

    I had a doc give a sample out - does that count?
     
  13. anonymous

    anonymous Guest

    Oh that was a samples of Nutella - very tastey love that stuff on toast!
     
  14. anonymous

    anonymous Guest

    Ha ha! Good one
     
  15. anonymous

    anonymous Guest

    This will be a blockbuster
     
  16. anonymous

    anonymous Guest

    ok
     
  17. anonymous

    anonymous Guest

    Boing job
     
  18. anonymous

    anonymous Guest

    It's the opposite of a blockbuster, straight to video. Boom
     
  19. anonymous

    anonymous Guest

    News alert! First Nucala prescription from Dr. Seuss.
     
  20. It is not indicated to was the spunk out of your throat